Futura Medical (FUM) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Sep 2024 07:00 AM
RNS
Update on US launch
19 Aug 2024 07:00 AM
RNS
Notice of Results
01 Aug 2024 07:05 AM
RNS
Update on US launch
01 Jul 2024 02:13 PM
RNS
Total Voting Rights
01 Jul 2024 07:00 AM
RNS
Nominated Adviser and Joint Broker
20 Jun 2024 04:12 PM
RNS
Result of AGM
20 Jun 2024 07:00 AM
RNS
AGM Statement
31 May 2024 07:00 AM
RNS
Block Listing Six Monthly Review
24 May 2024 07:00 AM
RNS
Notice of AGM and availability of Annual Report
29 Apr 2024 07:00 AM
RNS
Directors’ / PDMR Dealing and Grant of Options
10 Apr 2024 07:00 AM
RNS
Results for the Year ended 31 December 2023
25 Mar 2024 07:00 AM
RNS
Notice of Results and Investor Presentation
14 Feb 2024 07:00 AM
RNS
Eroxon to be available on prescription
06 Feb 2024 07:01 AM
RNS
Trading Update
06 Feb 2024 07:00 AM
RNS
Appointment of Joint Corporate Broker
17 Jan 2024 07:00 AM
RNS
Director/PDMR Dealing
17 Jan 2024 07:00 AM
RNS
Remuneration of Non-Exec Directors & Voting Rights
15 Jan 2024 07:00 AM
RNS
Futura Medical extends collaboration with Cooper
09 Jan 2024 07:00 AM
RNS
Appointment of Roy Davis as Non-Executive Director
30 Nov 2023 03:10 PM
RNS
Total Voting Rights
30 Nov 2023 03:10 PM
RNS
Block Listing Six Monthly Return
07 Nov 2023 07:00 AM
RNS
Futura expands partnership with M8 Pharmaceuticals
02 Nov 2023 03:34 PM
RNS
Eroxon Awarded “New Product of the Year” by Boots
31 Oct 2023 07:00 AM
RNS
Block Listing Application and Total Voting Rights
25 Oct 2023 07:00 AM
RNS
Eroxon® Granted Marketing Authorisation in Mexico
19 Oct 2023 07:00 AM
RNS
Eroxon Launches in the United Arab Emirates
10 Oct 2023 07:00 AM
RNS
Directors’/PDMR Dealing and Grant of Options
02 Oct 2023 07:00 AM
RNS
European Patent Granted for MED3000 until 2040
18 Sep 2023 07:00 AM
RNS
Futura Medical - Interim Results 2023
18 Aug 2023 07:00 AM
RNS
Futura Medical - Notice of Interim Results
09 Aug 2023 07:00 AM
RNS
MED3000 Commercialisation Approval in Saudi Arabia
31 Jul 2023 07:00 AM
RNS
Futura Medical - Total Voting Rights
18 Jul 2023 11:04 AM
RNS
Board Change
17 Jul 2023 07:00 AM
RNS
Futura/Haleon Enter US Commercialisation Agreement
30 Jun 2023 07:00 AM
RNS
Futura Medical - Total Voting Rights
23 Jun 2023 04:30 PM
RNS
Recording of Investor Seminar
22 Jun 2023 03:19 PM
RNS
Futura Medical Annual General Meeting Results
22 Jun 2023 07:00 AM
RNS
Futura Medical AGM Statement
19 Jun 2023 10:25 AM
RNS
Correction - TR-1: Notification of major holdings
16 Jun 2023 04:05 PM
RNS
TR-1: Notification of major holdings
12 Jun 2023 08:23 AM
RNS
Exercise of Warrants
12 Jun 2023 07:00 AM
RNS
MED3000 Granted US FDA Approval for OTC Sale
08 Jun 2023 07:00 AM
RNS
Futura Medical Announces Investor Seminar
31 May 2023 07:00 AM
RNS
Block Listing Six Monthly Return
26 May 2023 07:00 AM
RNS
Notice of AGM and availability of Annual Report
24 Apr 2023 07:00 AM
RNS
TR-1: Notification of major holdings
24 Apr 2023 07:00 AM
RNS
TR-1: Notification of major holdings
18 Apr 2023 07:00 AM
RNS
MED3000, Eroxon® UK Launch
06 Apr 2023 11:03 AM
RNS
Directors' / PDMR Dealing and Grant of Options
05 Apr 2023 07:00 AM
RNS
Full Year Results ended 31 December 2022

Futura Medical is the developer of innovative sexual health products, including lead product Eroxon®. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

FUM share price listed on AIM in 2003.

UK 100